Sustaining Remission of Psychotic Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

269

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Psychotic Depression
Interventions
DRUG

Sertraline + Olanzapine

Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening

DRUG

Sertraline + Placebo

Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.

Trial Locations (4)

10605

George Alexopoulos, MD, White Plains

15213

Ellen Whyte, MD, Pittsburgh

01605

Anthony Rothschild, MD, Worcester

Unknown

Alastair Flint, MD, Toronto

All Listed Sponsors
collaborator

University of Toronto

OTHER

collaborator

University of Massachusetts, Worcester

OTHER

collaborator

University of Pittsburgh

OTHER

lead

Weill Medical College of Cornell University

OTHER

NCT01427608 - Sustaining Remission of Psychotic Depression | Biotech Hunter | Biotech Hunter